

## Call for Posters

The call for papers is now open, and papers are invited for both short talks and posters. The closing dates are 31st January (oral) and 30th April (poster). Some posters will be selected for flash oral presentation.

## Who should attend

Medicinal chemists at all career stages. Scientists with an interest in drug discovery or new technologies that can be applied to the drug discovery process.

## Registration, Students and Bursaries

Registration is open, and details of registration fees may be found on our website. Discounted rates are offered to RSC members and some student bursaries are available.

## Venue and Accommodation

Hotel Comwell Borupgaard, Snekkersten is a 40-minute train or taxi journey from Copenhagen central railway station. Rooms are held at preferential rates at the conference venue, and the accommodation package includes dinners on Monday and Tuesday nights.

## Organising Committee

Sharan Bagal (Chair)	AstraZeneca, UK
Kevin Dack	LEO Pharma
Adrian Hall	UCB
Morten Jørgensen	Lundbeck
Malin Lemurell	AstraZeneca, Sweden

## Exhibition and Sponsorship

Contact the secretariat for details of exhibitor opportunities.

We are grateful to our confirmed sponsors,

LEO Pharma  
Lundbeck  
AstraZeneca

Additional sponsors are sought.



Lundbeck



AstraZeneca

## Secretariat Contact

Maggi Churchouse, 3 East Barn, Market Weston Road, Theltham, Diss IP22 1JJ, UK  
Telephone +44 (0)1359 221004, maggi@maggichurchouseevents.co.uk

**Websites:** [www.maggichurchouseevents.co.uk/bmcs](http://www.maggichurchouseevents.co.uk/bmcs)

Also: [www.rsc.org/bmcs](http://www.rsc.org/bmcs)



Comwell  
HOTELS

## Second announcement and call for papers



## 1st RSC Anglo-Nordic Medicinal Chemistry Symposium

Sunday-Wednesday, 11th-14th June 2017

Hotel Comwell Borupgaard, Copenhagen, Denmark



BIOLOGICAL AND  
MEDICINAL  
CHEMISTRY  
SECTOR



## Programme

### Sunday 11th June

18:00 Registration, welcome reception and buffet supper  
21:00 Close

### Monday 12th June

08:30 Registration

#### **Session 1 - Kinases**

Session chair: **Sharan Bagal**, AstraZeneca, UK  
09:00 *Structure-guided discovery of potent and selective inhibitors of Erk1/2 from a weak and promiscuous chemical start point*  
**Richard Ward**, AstraZeneca, UK  
09:40 *Discovery of selective and efficacious Syk inhibitors*  
**Gebhard Thoma**, Novartis, Switzerland  
10:20 Refreshments  
10:40 *Spleen tyrosine kinase inhibitors for the topical treatment of inflammatory skin diseases*  
**Mike Barker**, GlaxoSmithKline, UK  
11:20 *Identification of Vps34 as a key off-target liability in the search for an oral PI3Kinase delta inhibitor for the treatment of respiratory disease*  
**Zoë Henley**, GlaxoSmithKline, UK  
12:00 *Lead generation strategies: discovery of a potent, selective and efficient IRAK4 clinical candidate from fragment-based drug design*  
**Frank Lovering**, Pfizer, USA  
12:40 Lunch  
13:30 Flash poster presentations  
14:00 Poster session and refreshments

#### **Session 2 - Enabling Science and Technologies (part I)**

Session chair - **Morten Jørgensen**, Lundbeck, Denmark  
14:30 *DNA-encoded library technology: from hits to clinical candidate*  
**Thomas Franch**, Nuevolution, Denmark  
15:25 *Structure-based screening for GPCR ligands from fragment and lead-like chemical space*  
**Jens Carlsson**, Uppsala University, Sweden  
16:20 *Recent progress in structure-based drug design approaches to GPCRs*  
**Steve Watson**, Heptares, UK  
16:50 Refreshments  
17:20 *Late stage functionalization and complex human metabolite synthesis: microbial solutions for DMPK scientists and medicinal chemists*  
**Liam Evans**, Hypha Discovery, UK  
17:35 *Drug discovery - guided by the Cellular Thermal Shift Assay (CETSA)*  
**Daniel Martinez Molina**, Pelago Bioscience, Sweden  
17:50 *Conformetrix and its application to drug discovery*  
**Thorsten Nowak**, C4X Discovery, UK  
18:05 *Fragment screening in lead discovery by Weak Affinity Chromatography (WAC)*  
**Johan Evanäs**, Red Glead Discovery, and **Björn Walse**, SARomics Biostructures  
18:20 Close  
19:00 Dinner (for residents only)

## Programme (continued)

### Tuesday, 13th June

08:30 Registration

#### **Session 3 - GPCRs and NHRs**

Session chair - **Adrian Hall**, UCB, Belgium  
09:00 *The development of GPR6 inverse agonists for the treatment of Parkinson's disease*  
**Holger Monenschein**, Takeda, USA  
09:40 *Discovery of mineralocorticoid receptor modulators separating kidney protection from electrolyte effects*  
**Kenneth Granberg**, AstraZeneca, Sweden  
10:20 Refreshments  
10:40 *Free fatty acid receptors as therapeutic targets*  
**Trond Ulven**, University of Southern Denmark (SDU), Denmark  
11:20 *Topical drug design: 'Super-Soft' Selective Glucocorticoid Receptor Agonist (SEGRA-ss) for dermatology*  
**Kevin Neil Dack**, LEO Pharma A/S, Denmark  
12:00 *Development of M1 positive allosteric modulators for cognition*  
**Doug Beshore**, Merck, USA  
12:45 Lunch  
13:30 Free time to enjoy the spa and the hotel

#### **Session 4 - Enabling Science and Technologies (part II)**

Session chair - **Malin Lemurell**, AstraZeneca, Sweden  
16:30 *New discoveries within phosphorothioate LNA*  
**Erik Daa Funder**, Roche Innovation Center Copenhagen, Denmark  
17:00 *Phenotypic screening for small molecules that can enhance cardiac regeneration*  
**Anneli Nordqvist**, AstraZeneca, Sweden  
17:30 *Bicyclic peptide drug conjugates and applications in molecular-targeted cancer therapy*  
**Daniel Teufel**, Bicycle Therapeutics, UK  
18:00 *Medicinal chemistry beyond small molecule inhibition: new possibilities through induced intracellular protein degradation*  
**John Harling**, GlaxoSmithKline, UK  
18:30 Close  
19:00 Conference dinner (for residents only)

### Wednesday, 14th June

08:30 Registration

#### **Session 5 - Enzymes and Transporters**

Session chair - **Kevin N Dack**, LEO Pharma, Denmark  
09:00 *Impact of transporters on the DMPK properties of drugs*  
**Katherine Fenner**, AstraZeneca, UK  
09:45 *Development of potent and selective inhibitors of MTH1 to probe its role in cancer cell survival*  
**James Scott**, AstraZeneca, UK  
10:30 Refreshments  
11:00 *BACE inhibitors: optimization of druglike properties via modulation of pKa*  
**Harrie Gijzen**, Janssen Pharmaceutica, Belgium  
11:45 *The discovery of potent and orally available Dot1L inhibitors by fragment growing, fragment linking and fragmentation approaches*  
**Christoph Gaul**, Novartis, Switzerland  
12:30 Close  
12:40 Lunch and depart